11.25.25 -- The 15% Tariff: A Modest Jolt Or Deeper Disruption?

To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Among other benefits, immunoprecipitation coupled with mass spectrometry (IP-MS) can help compare CAR constructs, evaluate manufacturing processes, and monitor changes in protein interactions.

Streamline cell therapy development by transforming complex cellular characteristics into a predictive, multiparametric metric that guides the selection of high-potential starting material.

Hear how one family, driven by urgency, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.

Infectious disease mAb therapies are entering clinical trials at a record pace. Review the trends driving the use of mAb treatments as well as key considerations to remain competitive in the race to market.

Uncover how a model was developed to address the multifactorial nature of large-scale transfection, where variables like viable cell density (VCD) and DNA amount jointly influence efficiency.

Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.

In this interview, Mike Kadan, Ph.D., MBA, Chief Operating Officer of Vector BioMed, shares how the company is reimagining viral vector manufacturing through a purpose-built, modular platform.

Here, we explain how our engineered Rep-Cap plasmids dramatically enhance AAV vector yield, quality, and scalability, offering a powerful, next-generation solution to overcome manufacturing challenges.

Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success.

Consider the advantages of platform processes for advancing novel gene therapies, the role of robust partnerships, and how these collaborative efforts are shaping the future of therapeutic development.

The unique challenges of a viral vector asset or molecule require high-throughput processes and analytical development solutions, coupled with extensive industry experience.

In this study, we present a comprehensive analysis of various published and newly developed dsDNA conversion processes that were tested using the same sequencing chemistry.

Gain insights into how standardized quality controls, robust analytics, and streamlined processes can improve efficiency, reliability, and scalability across the development lifecycle.

LEG14 nuclease and mbDNA templates enable efficient, non-viral TCR knock-in in T-cells, doubling NYESO-1 targeting efficiency compared to plasmid-based approaches.

From early development to full-scale global commercialization, our proven track record with international regulatory agencies underscores our ability to navigate complex requirements.

Follow along as we recall our experience in providing clinical CAR-T products to the clinic for more than five years and our plans to deliver a pivotal drug product for patients.

Whether you need precise single-base edits, large safe-harbor insertions, or other knock-in/knock-out changes, our exclusive technologies and expert scientists deliver exceptional results.

We simply need your gene of interest (GOI) to provide swift, top-notch cGMP material using our optimized one-stream platform to help reduce cost and expedite the journey to clinical trials.